In recent analyst actions, Bernstein's Eve Burstein has adjusted the firm's price target for PacBio (PACB, Financial), reducing it from $2 to $1.50. However, the firm maintains its Outperform rating on the stock despite the downward revision. This decision reflects ongoing concerns about several economic and funding challenges currently affecting the health sector.
A range of factors contributed to this outlook, including the impact of tariffs, uncertainties surrounding the National Institutes of Health (NIH) funding, and potential disruptions from the Health and Human Services (HHS) department's actions in the pharmaceutical sector. Bernstein suggests that these issues are not just theoretical as they are becoming evident in the sector's financial metrics.
As the firm transitions into the first quarter, it does so with a cautious stance, recognizing that the hoped-for recovery in life sciences tools is not unfolding as anticipated at the beginning of the year. The reduced price target mirrors this cautious outlook while still projecting potential positive performance for PacBio shares.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 12 analysts, the average target price for Pacific Biosciences of California Inc (PACB, Financial) is $2.15 with a high estimate of $3.50 and a low estimate of $1.00. The average target implies an upside of 68.96% from the current price of $1.27. More detailed estimate data can be found on the Pacific Biosciences of California Inc (PACB) Forecast page.
Based on the consensus recommendation from 15 brokerage firms, Pacific Biosciences of California Inc's (PACB, Financial) average brokerage recommendation is currently 2.4, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Pacific Biosciences of California Inc (PACB, Financial) in one year is $5.18, suggesting a upside of 307.87% from the current price of $1.27. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Pacific Biosciences of California Inc (PACB) Summary page.
